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As a result of multiple technological and practical
advances, high-throughput sequencing, known more
commonly as “next-generation” sequencing (NGS), can
now be incorporated into standard clinical practice.
Whereas early protocols relied on samples that were
harvested outside of typical clinical pathology
workflows, standard formalin-fixed, paraffin-embedded
specimens can more regularly be used as starting
materials for NGS. Furthermore, protocols for the
analysis and interpretation of NGS data, as well as
knowledge bases, are being amassed, allowing
clinicians to act more easily on genomic information
at the point of care for patients. In parallel, new
therapies that target somatically mutated genes
identified through clinical NGS are gaining US Food
and Drug Administration (FDA) approval, and novel
clinical trial designs are emerging in which genetic
identifiers are given equal weight to histology. For
clinical oncology providers, understanding the
potential and the limitations of DNA sequencing will
be crucial for providing genomically driven care in this
era of precision medicine.sequence at each spot can then be inferred by a computerIntroduction
Many biological discoveries about cancer have been the
product of a reductionist approach, which focuses on
modeling phenomena with as few major actors and in-
teractions as possible [1, 2]. This reductionist thinking
led the initial theories on carcinogenesis to be centered
on how many “hits” or genetic mutations were necessary
for a tumor to develop. It was assumed that each type of
cancer would progress through a similar, if not identical,
process of genetic hits. Indeed, there are a handful of* Correspondence: eliezerm_vanallen@dfci.harvard.edu
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that feature a single and pathognomonic DNA mutation.
Working on this assumption, early methods to explore
the genomic foundations of different cancers involved
targeted exploration of specific variants and genes in a
low-throughput fashion [3]. However, most cancers are
genetically complex, and are better defined by the activa-
tion of signaling pathways rather than a defined set of
mutations. The success of the Human Genome Project
inspired similar projects looking at the genome in vari-
ous cancers [4]. That success, along with the increased
affordability and reliability of sequencing [5], has led to
the integration of genome science into clinical practice.
The use of these data to assist in diagnosis is generally
referred to as precision medicine [6, 7].
Next-generation sequencing (NGS), also known as
massively parallel sequencing, represents an effective
way to capture a large amount of genomic information
about a cancer. Most NGS technologies revolve around
sequencing by synthesis [5]. Each DNA fragment to be
sequenced is bound to an array, and then DNA polymerase
adds labeled nucleotides sequentially. A high-resolution
camera captures the signal from each nucleotide becoming
integrated and notes the spatial coordinates and time. The
program to generate a contiguous DNA sequence, referred
to as a read.
Multiple technological enhancements have allowed
NGS to be more readily implemented in a clinical work-
flow (Fig. 1). Samples now no longer need to be handled
differently from standard diagnostic specimens, and re-
cent advances have even enabled increasingly complex
genomic data to be derived from a patient’s peripheral
blood. The concept of precision medicine goes hand in
hand with an understanding of the cancer genome as de-
termined by NGS. In this review, we will explore the
expanding NGS methodologies, analytical methods, and
clinical applications that are driving precision cancer
medicine.Access article distributed under the terms of the Creative Commons Attribution
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Fig. 1 A summary of the workflow for NGS sequencing in oncology. The first row outlines selecting the appropriate sample and assay. Turning
raw data into clinically actionable information is covered in the second row. The third row looks at how NGS may be used in the continued
monitoring of disease. ctDNA circulating tumor DNA, FFPE formalin-fixed, paraffin-embedded specimen
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Before the development of NGS, tumor genotyping was
performed only on specific genomic loci that were
known to be frequently mutated in cancer, which are
known as “hotspots”. These approaches were best suited
to recurrent activating mutations in oncogenes, such as
in the KRAS gene in colon [8] and lung cancer [9]. How-
ever, these approaches were insufficient to identify alter-
ations in tumor suppressors (in which an alteration
anywhere in the gene may impact its function) or the in-
creasingly complex area of “long tail” hotspot alterations
in oncogenes [10]. Thus, current assay options involveOncogene GUS1
Fig. 2 The trade-off between coverage and amount of the genome covere
tumor suppressor and two genes of uncertain significance (GUS). For visual
genes of interest. Whole-exome sequencing is able to cover each gene wit
specific base with more than one read. Bear in mind, this figure is vastly un
depth goals should be much higherapproaches that may capture known cancer genes
(“gene panels”), whole-exome, whole-genome and/or
whole-transcriptome approaches. There are several
trade-offs to increasing the portion of the genome
that is sequenced. The first is a loss of coverage for
the same amount of sequencing (Fig. 2). Coverage, or
depth, is defined as the average number of mappable
reads at a given locus in your panel. Lower coverage
limits the ability to confidently call a variant of low
allele fraction to be biologically real and not a tech-
nical artifact. A second is that whole-genome and





d. A hypothetical region of the genome contains an oncogene, a
simplicity, we show ten reads, which will get sequencing depth at
h fewer reads, whereas whole-genome sequencing rarely covers a
derstating the relative size of intergenic regions. Realistic sequencing
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[11], which may uncover incidental clinically relevant
inherited disorders (see below).
When considering a gene panel, another decision is
whether the technology should be based on hybrid cap-
ture or amplicon sequencing (Fig. 3). Amplicon sequen-
cing enriches target genes by PCR with a set of primers
for exons of selected genes prior to NGS analysis [12].
These protocols have the advantage of less required in-
put DNA and less turnaround time than hybrid capture
methods, which is critical for clinical application, but
potentially PCR amplification can bias the observed al-
lele fraction. It also pulls information out of a lower per-
centage of starting material, further increasing the
chance of bias in calling copy number variations. The in-
formatics analysis is relatively easy, as any read that does
not map to a locus between primers can be disregarded.
A downside of this simplicity is that the assay is inher-
ently unable to detect unexpected fusions, because either
the 5' or 3' primer would fail to bind the translocated
DNA.
In hybrid capture, relevant DNA sequences are hybrid-
ized to probes, which are biotinylated. The biotin is
bound to streptavidin beads and then non-bound DNA
is washed away [13]. This has the advantage of more re-
liable detection of copy number changes, although some
research groups are using amplicon-based sequencing to
detect copy number changes as well [14]. The disadvan-
tages of hybrid capture include a higher required depth
of sequencing and a more advanced bioinformatics plat-
form (see below). Hybrid capture does have the ability to
detect fusion proteins, as they will be pulled down withExon 2 Ex
Fig. 3 Amplicon-based and hybrid capture sequencing methods. The figur
exons 2 and 3. The DNA is sheared either in recovery from being formalin-
adapter binding. Hybrid capture involves probes that are designed with ho
fragmented DNA can contain information beyond the boundary of the exo
amplicon-based sequencing, only probes that contain the complementary
outside of the primers is sequencedthe baited DNA. Fusions are still a challenge for hybrid
capture, however, because while the fusion protein may
be common, the breakpoint itself is found over the full
range of an intron [15]. If there is a high suspicion that a
sample may contain clinically important fusions, an
assay based on cDNA should be considered. These as-
says will show the fused exon–exon junctions, obviating
the need to find the genomic breakpoint [16]. Calling
variants and DNA copy number changes can be difficult
with both methods (as well as with microarray-based as-
says) when there is high tumor heterogeneity [17] or low
tumor purity [18]. For example, a high copy number
gain in a small number of cells may be interpreted as a
widespread low copy number gain. Thus, putatively ac-
tionable copy number variations are typically validated
by fluorescent in situ hybridization in clinical settings.
Choice of clinical sample
Most specimens that are examined by anatomical pa-
thologists are fixed in formalin (4 % formaldehyde) and
embedded in paraffin (FFPE). The formalin introduces
crosslinks that can both fragment DNA and cause chem-
ical alterations that may alter sequencing results [19].
Early studies demonstrated that using FFPE specimens
in PCR-based sequencing led to more errors than using
frozen specimens [20]. Some projects, including The
Cancer Genome Atlas (TCGA), required the use of fresh
frozen tissue [21]. There has been great progress in al-
tering DNA extraction methods such that FFPE speci-
mens are just as useful for NGS as fresh frozen samples
[22]. While there have been some early attempts at using





e shows a hypothetical gene for which a clinical assay sequences
fixed and paraffin-embedded, or deliberately to allow for sequencing
mology to the gene of interest and bind cDNA. Notice that the
n. The probes are biotinylated and unbound DNA is washed away. In
sequence for both primers are amplified. Therefore, no information
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used clinically, and the reliability of FFPE versus fro-
zen samples is less well established. Clinicians should
feel comfortable requesting NGS on FFPE samples,
and do not necessarily have to handle the specimens
differently from other diagnostic samples.
For most cancers, the standard pathological diagno-
sis will require a direct sample of tissue for biopsy.
However, many research groups are exploring the
diagnostic and therapeutic utility of “liquid biopsies”.
One such source of genetic material for disease moni-
toring are circulating tumor cells (CTCs). These suf-
fer from a low frequency (approximately 1 cell in
106–108 total circulating cells) and must, therefore, go
through an enrichment step. A large number of CTC
collection and sequencing protocols have been re-
ported and are being evaluated prospectively [25, 26].
Alternatively, DNA released from apoptotic cells in
the tumor can be assayed from the peripheral blood,
and is usually referred to as circulating tumor DNA
(ctDNA). Progress in utilizing ctDNA was recently
reviewed [27], with the authors concluding that this
approach shows great promise for the purpose of de-
tecting minimal residual disease [28], or helping to
improve diagnosis by looking for mutations specific-
ally associated with a particular disease type [29].
RNA is much less stable than DNA in circulating
blood, but RNA species can be preserved in extracel-
lular vesicles and information about tumor recurrence
can be gleaned from them as well [30]. However, re-
producibility has plagued RNA-based studies, and
RNA assays are not yet ready for clinical use [31].
Tumor heterogeneity is both a challenge for liquid biop-
sies and the reason they can be more useful than tissue bi-
opsies [32]. Initially, mutations with a low allele fraction
owing to only being present in a subset of tumor cells may
be missed by liquid biopsies, as the low amount of DNA
input to the assay is compounded by the low incidence of
the mutation. This makes distinguishing low allele fraction
mutants from errors that are inherent to high-throughput
sequencing very difficult (see below). However, the ability
for minimally invasive samples to be sequenced repeatedly
over time will allow for faster recognition of known resist-
ance mutations. Sequencing artifacts should be random,
but sequences that appear serially can be weighted and
followed more closely. It should also be noted that er-
rors in aligning reads to the correct locus will give
what appear to be recurrent mutations, so all muta-
tions that are used for serial tracking of tumor bur-
den should be manually reviewed. Overall, there is
much promise in sequencing tumor DNA from per-
ipheral blood, but its use is still under investigation
and clinicians should rely on other methods for track-
ing disease progression.Clinical NGS data analysis
An additional area of innovation for clinical NGS in-
volves bioinformatic analysis of raw genomic data and
rapid clinical interpretation for consideration by the
treating clinician. The first step in this process is to as-
sign a genetic location to the read by mapping it on a
reference genome [3]. Some percentage of the reads will
be “unmappable”, that is, the software cannot assign the
sequence to a unique genomic location [33]. An individ-
ual genome will have a number of deviations from a ref-
erence genome, referred to as single nucleotide variants
(SNVs), and/or structural alterations such as insertions,
deletions or translocations. Somatic mutation analysis,
as is done in cancer, involves a number of additional
challenges. There are robust algorithms available for
identifying many clinically relevant alterations that
occur as point mutations, short insertions or dele-
tions, or copy number aberrations in clinical samples
analyzed by NGS [34].
However, as DNA mutations accumulate within a
tumor, there can be considerable sequence heterogeneity
even within a single primary tumor [17]. It can be very
challenging to discern whether a read of a low allele
fraction represents a true mutation that exists within a
subset of tumor cells or is an artifact that should be dis-
carded. While retrospective research endeavors may not
require the identification of all possible clinically action-
able alterations in a cohort study, prospective clinical
cancer genomics requires increased sensitivity to detect
low allelic fraction alterations in impure tumor samples
that may impact an individual patient’s care. These is-
sues can be exacerbated by low amount of tumor relative
to normal tissue within the sample and mitigated by
having more reads, that is, greater coverage. If a detected
mutation is the result of a low allele fraction within the
sample, the number of reads will rise proportionally with
total reads, whereas if it is a technical artifact, the num-
ber of reads should be random and can be eliminated
from analysis. Estimating tumor percentage from a
standard pathology specimen should be helpful for giv-
ing an expected allele fraction within the sample, but is
prone to very high inter-observer variation [35].
A second challenge is frequent DNA fusions, which
represent a significant component of the clinically ac-
tionable spectrum of alterations in oncology (for ex-
ample, ALK fusions, BCR-ABL fusions). Within NGS
data, these events will cause both ends of a read to be
mappable, but the whole contiguous sequence is not.
This is referred to as a split read, and can be challenging
in the presence of a high number of structural rear-
rangements, such as in cancers with chromothripsis
[36]. Notably, since most clinically relevant somatic fu-
sions occur outside of coding regions, whole-exome se-
quencing assays often miss these variants, and gene
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tories will also be unable to identify these fusion prod-
ucts. Thus, when analyzing a clinical NGS data set, it is
critical to understand the analytical limitations of a given
assay as represented in the downstream data analysis.
Clinical interpretation of NGS data
After identification of the set of alterations within a
given patient’s tumor, many cases will yield a small set of
clinically relevant events as well as a long list of sequen-
cing variants of uncertain significance. An emerging
body of interpretation algorithms that automate the clin-
ical relevance of the alterations will enable more rapid
clinical interpretation of cancer genomic sequencing
data. For instance, one algorithm called PHIAL applies a
heuristic method to rank alterations by clinical and bio-
logical relevance, followed by intra-sample pathway ana-
lysis to determine potentially druggable nodes [22, 37].
As such approaches mature, they will be better equipped
to apply tumor-specific “priors” to the genomic data,
along with genotype–phenotype therapeutic outcomes
data, to enable probabilistic approaches to ranking
tumor genomic alterations by clinical relevance.
Furthermore, there are several databases that can be
accessed to evaluate the clinical significance of muta-
tions. The first level of analysis is whether the variant
you are interested in has been seen before in published
reports. A simple concept is that driver mutations are
more likely to recur across multiple patients and tumor
types. The most common databases used (Table 1) are
the Catalog of Somatic Mutations in Man (COSMIC)
[38, 39], and TCGA (available for data exploration at
multiple sites) [40, 41]. After whittling the mutations
down to those that are recurrent, information about
therapies and prognostic information can be found at a
number of locations. Cancer centers that have created
and host these databases include MD Anderson’s Per-
sonalized Cancer Therapy [42, 43], Vanderbilt’s My Can-
cer Genome [44, 45], and the Broad Institute’s TARGET
[22, 46]. Each database contains useful information and
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Each database is listed with hosting institution, website, and the primary search terthere will have to be more steps to improve data sharing,
with the creation of a central repository of both se-
quences and de-identified patient information, but there
is no consensus yet for how this process should happen.
Finally, for NGS technologies that require both som-
atic and germline testing (for example, whole-exome
and whole-genome sequencing), the American College
of Medical Genetics has released guidelines outlining
which variants should always be reported to patients re-
gardless of whether they are relevant to the presenting
illness [47]. Since most of these genes involve non-
cancer-related syndromes, there is an increasing need
for oncologists to be prepared to receive results that
bring up unexpected inherited genetic issues [48]. How-
ever, the germline component to clinical oncology NGS
testing may have significant diagnostic and therapeutic
utility, as demonstrated by the identification of pathogenic
germline alterations in men with castration-resistant pros-
tate cancer who respond to PARP inhibition [49], and its
role in this arena is evolving rapidly.
NGS utility
There are three general ways that NGS can aid a clin-
ician. The first is with diagnosis; tumor subtypes that
only a few years ago were defined by morphologic cri-
teria are now defined by genetic mutations, either inclu-
sively or exclusively. For example, 15/15 patients in a
study looking at fibrolamellar hepatocellular carcinoma
had an in-frame fusion between DNAJB1 and PRKACA
[50]. The second is finding an appropriate “targeted
therapy”, as an increasing number of therapies have indi-
cations based on DNA sequencing results (Table 2). Pa-
tients who lack the mutation targeted by a drug will not
only fail to benefit, but can actually be harmed by in-
appropriate targeted therapies [51]. The third point at
which clinicians stand to benefit from NGS is when a
patient stops responding to a targeted therapy with
known resistance mutations. In some instances, the re-
sistance mutation may be limited to one or a few loci.
For example, resistance to EGFR targeted therapies in
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Table 2 FDA-approved drugs with a companion diagnostic
Drug Disease DNA mutation Action
Imatinib, Dasatinib, Nilotinib, Bosutinib Chronic myelogenous leukemia BCR-ABL1 fusion Indication for therapy
Ponatinib Chronic myelogenous leukemia BCR-ABL1 fusion Only indicated for T315I mutations
T315I resistance mutation
Erlotinib, Afatinib Lung adenocarcinoma EGFR Indication for therapy
Exon 19 deletions
L858R
Vemurafenib, Dabrafenib Melanoma BRAF V600E Indication for therapy
Tramatenib Melanoma BRAF V600E/K Indication for therapy
Crizotinib Lung cancer ALK gene fusions Indication for therapy
Cetuximab Colon cancer KRAS codon 12, 13 Contraindication to therapy
Olaparib Ovarian cancer BRCA1 and BRCA2 mutations Indication for therapy
Each drug has a specific genomic result that is part of its indication for use. FDA Food and Drug Administration
Gagan and Van Allen Genome Medicine  (2015) 7:80 Page 6 of 10and can possibly be overcome by merely switching to a
different agent [52]. However, glioblastoma can become
resistant to EGFR targeted therapies via a complicated
epigenetic regulation [53]. NGS allows a more complete
overview of tumor dynamics, and is more likely to shed
light on idiopathic resistance mechanisms than a single
gene assay.
If a patient has failed conventional therapy, NGS can
be immensely helpful for identifying and enrolling them
into an appropriate clinical trial. There are two types of
clinical trial structure that require patients to have their










Fig. 4 An illustration of new clinical trial designs. Basket and umbrella trials
trial. Basket trials are designed around specific mutations, regardless of the
site and then split into conventional therapy and precision medicine armsan umbrella trial, patients with a type of morphologically
defined cancer are assigned to a treatment arm on the
basis of the genetic mutations detected in their tumor.
Umbrella trials comprise many different treatment arms
under the umbrella of a single trial. In essence, umbrella
trials test whether a “precision” approach leads to better
outcomes within a traditional diagnosis (for example,
lung adenocarcinoma) than standard of care approaches.
In a bucket trial (also called a basket trial), cancers of
different types are clustered exclusively by genetic muta-
tion. The US National Cancer Institute has recognized
the potential of the NGS followed by targeted therapyBasket
Umbrella
tional Targeted 
nt – Arm 1 KRAS agent – Arm 2
both incorporate genomic data into the basic construction of the
primary tumor site. Umbrella trials are first separated by primary tumor
Gagan and Van Allen Genome Medicine  (2015) 7:80 Page 7 of 10approach by setting up the Molecular Analysis for Ther-
apy Choice (MATCH) Program. Biopsies from tumors
from as many as 3000 patients will undergo NGS to
identify individuals whose tumors have genetic abnor-
malities that may respond to selected targeted drugs. As
many as 1000 patients will then be assigned to one of
the phase II trials, with assignment based not on their
type of cancer but on the genetic abnormality that is
thought to be driving their cancer [54]. The nuances of
constructing these types of trials are beyond the scope of
this review and have been covered well previously [55].
Efforts are ongoing to determine prognostic bio-
markers in clinical oncology. Many false starts have been
caused by extrapolating from what is called overfitting,
which is building a precise model from a small, non-
representative data set. Determining prognosis on the
basis of non-druggable mutations from NGS has tended
to follow from this tradition. Certain mutations, such as
TP53 [56], portend a poor prognosis in almost all clin-
ical situations. Others, such as ASXL1, are only associ-
ated with a particular disease [57]. Mutations in IDH1
and IDH2 indicate a better prognosis in glioma [58], but
often show contradictory results in myeloid malignanciesConsider patient
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Fig. 5 A representative clinical example of how NGS is utilized in recurrent
fitted to the outline in Fig. 1. In a lung adenocarcinoma, there are a numbe
treated with erlotinib. There are actually now two levels of resistance that c
paraffin-embedded specimen[59], although this may change as targeted agents move
through clinical trials [60]. Caution should be used when
communicating prognostic information to patients.
Clinical NGS case study
As an example that demonstrates the utility of clinical
NGS, we look at the fictional scenario of a patient
who presents with a newly diagnosed lung adenocar-
cinoma (Fig. 5). Targeted therapies that affect multiple
recurrent alterations in lung adenocarcinoma have
been developed, including those that target EGFR mu-
tations, MET amplification, and ALK or ROS1 fusions,
among others [61]. Thus, a targeted gene panel that
encompasses these events would be most commonly
applied. DNA can be harvested from the FFPE tumor
block obtained from a diagnostic biopsy sample, and
targeted NGS sequencing can be used to identify the
set of somatic point mutations, short insertions/dele-
tions, copy number alterations, and oncogenic fusion
events. In this case, let us say that the resulting inter
pretation of the set of variants reveals two muta-
tions: EGFR L858R (allelic fraction of 35 %) and
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lung adenocarcinoma. The illustrative case from the text has been
r of actionable mutations; this case shows a canonical EGFR mutation,
an develop, illustrated in rows 3 and 4. FFPE formalin-fixed,
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for erlotinib. The TP53 mutation likely confers a
worse prognosis [62], but management does not
change as a result. The patient can be followed by
both radiology and/or ctDNA assays, with the L858R
mutation as a marker of tumor DNA [29]. The pa-
tient has a good initial response but develops a recur-
rence after 6 months. Repeat biopsy and NGS testing
is obtained, which reveals the L858R mutation with a
35 % allele fraction and a second EGFR T790M muta-
tion with a 12 % allele fraction. From this it would
be possible to infer that the second mutation in
EGFR is derived from a resistant subclone that has
emerged as a result of therapy, as indicated by the
lower allelic fraction compared with the original
EGFR mutation. The databases show that this is a
common resistance mutation for erlotinib, but can be
targeted by newer agents [52, 63]. The patient should
continue to be followed, because these newer agents
can also trigger the development of additional resist-
ance mutations [52, 64, 65] in EGFR or other genes
(thereby highlighting the need for broader testing
using NGS beyond limited gene testing to ensure
identification of the resistance alteration).Future directions
While much information can be gleaned from a
tumor DNA sequence, we must be mindful that DNA
itself is rather inert. Better information about the
functionality of a cancer can be obtained by integrat-
ing information from different modalities. RNA se-
quencing could give information about the relative
expression of a mutated gene. Approaches in mass
spectrometry are giving a clearer picture of the prote-
omics of cancer [66]. TCGA data were collected using
a number of different modalities, and are available for
several tumor types, and while useful information can
be gleaned at different levels, tying everything together re-
mains a prodigious challenge [67]. The methods used to
predict phenotypes from integrated -omics data have been
reviewed recently [68].
Furthermore, immunotherapies are quickly gaining
prevalence for cancer therapy, especially for use in
melanoma [69]. NGS sequencing could become very
important for predicting responses to immunotherapy.
Neoantigens — that is, antigens that are created by
somatic mutations — are correlated with the overall
rate of somatic mutation and clinical response [70].
Immune response is mediated by T-cell recognition of
these neoantigens [71]. Exome sequencing can be
paired with mass spectrometry to determine which
neoantigens are successfully presented by the major
histocompatibility complex (MHC) [72].Conclusion
NGS is inextricably intertwined with the realization of
precision medicine in oncology. While it is unlikely to
obviate traditional pathologic diagnosis in its current
state, it allows a more complete picture of cancer eti-
ology than can be seen with any other modality. How-
ever, precision cancer medicine and large-scale NGS
testing will require novel approaches towards ensuring
evidence-based medicine. Treating each genetic abnor-
mality as an independent variable when hundreds or
thousands are queried in every patient will require new
trial designs and statistical methods to ensure the utility
of these approaches. Broadly, clinicians and translational
researchers will need to continue to engage in direct dia-
log, both within and across institutions, to advance the
integration of genomic information and clinical pheno-
types, and enable precision cancer medicine through
NGS approaches.
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